Fadi Haddad, Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston, shared a post on X/Twitter:
“Out in NEJM rusfertide in Polycythemia vera
Rusfertide = hepcidin mimetic
S/C weekly
N=59 in Phase 2 (Rusfertide=30, Placebo=29)
Ht control and absence of phlebotomy, 60% vs 17%
Improved symptoms with rusfertide”
Source: Fadi Haddad/X